PT2691109E - Prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2 - Google Patents

Prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2 Download PDF

Info

Publication number
PT2691109E
PT2691109E PT127121069T PT12712106T PT2691109E PT 2691109 E PT2691109 E PT 2691109E PT 127121069 T PT127121069 T PT 127121069T PT 12712106 T PT12712106 T PT 12712106T PT 2691109 E PT2691109 E PT 2691109E
Authority
PT
Portugal
Prior art keywords
hypoglycaemia
patients
prevention
diabetes mellitus
mellitus type
Prior art date
Application number
PT127121069T
Other languages
English (en)
Inventor
Gabor Boka
Louise Silvestre
Patrick Miossec
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44504331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2691109(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PT2691109E publication Critical patent/PT2691109E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
PT127121069T 2011-03-29 2012-03-29 Prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2 PT2691109E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11160270 2011-03-29

Publications (1)

Publication Number Publication Date
PT2691109E true PT2691109E (pt) 2015-10-30

Family

ID=44504331

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127121069T PT2691109E (pt) 2011-03-29 2012-03-29 Prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2

Country Status (20)

Country Link
US (2) US20120277147A1 (pt)
EP (1) EP2691109B1 (pt)
JP (1) JP6410600B2 (pt)
KR (1) KR20140033030A (pt)
CN (1) CN103582491B (pt)
AU (1) AU2012234180B2 (pt)
BR (1) BR112013024973B1 (pt)
CA (1) CA2830811A1 (pt)
CY (1) CY1116799T1 (pt)
DK (1) DK2691109T3 (pt)
ES (1) ES2549955T3 (pt)
HK (1) HK1192725A1 (pt)
HR (1) HRP20151087T1 (pt)
HU (1) HUE025716T2 (pt)
MX (1) MX336657B (pt)
PL (1) PL2691109T3 (pt)
PT (1) PT2691109E (pt)
RU (1) RU2583134C2 (pt)
SI (1) SI2691109T1 (pt)
WO (1) WO2012130955A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344293B (es) 2008-10-17 2016-12-13 Sanofi Aventis Deutschland Combinacion de una insulina y un agonista de glp-1.
KR101772372B1 (ko) 2009-11-13 2017-08-29 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
MX2016008977A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de insulina aspart estabilizadas.
CA2932875A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
TN2017000235A1 (en) 2014-12-12 2018-10-19 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2020112253A2 (en) * 2018-10-16 2020-06-04 The Board Of Regents Of The University Of Oklahoma Uses of glucagon-like peptide-1 receptor agonists for treating trauma-induced hearing loss

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
ATE390140T1 (de) * 1999-11-03 2008-04-15 Bristol Myers Squibb Co Arzneimittel, umfassend eine kombination aus metformin und glibenclamide
CN1413582A (zh) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 盐酸二甲双胍肠溶片及其制备方法
US7902254B1 (en) * 2005-06-27 2011-03-08 Newtree Co., Ltd. Method for treating conditions mediated by PPAR using macelignan
RU2440143C2 (ru) * 2005-09-20 2012-01-20 Новартис Аг Применение ингибитора dpp-iv для снижения приступов гликемии
MX344293B (es) * 2008-10-17 2016-12-13 Sanofi Aventis Deutschland Combinacion de una insulina y un agonista de glp-1.

Also Published As

Publication number Publication date
US20120277147A1 (en) 2012-11-01
MX336657B (es) 2016-01-27
KR20140033030A (ko) 2014-03-17
EP2691109A1 (en) 2014-02-05
ES2549955T3 (es) 2015-11-03
JP2014514289A (ja) 2014-06-19
CY1116799T1 (el) 2017-03-15
HRP20151087T1 (hr) 2015-11-20
WO2012130955A1 (en) 2012-10-04
PL2691109T3 (pl) 2015-12-31
CA2830811A1 (en) 2012-10-04
BR112013024973A2 (pt) 2016-08-30
HK1192725A1 (en) 2014-08-29
AU2012234180B2 (en) 2017-02-16
DK2691109T3 (en) 2015-10-19
SI2691109T1 (sl) 2015-11-30
AU2012234180A1 (en) 2013-10-17
MX2013011174A (es) 2013-11-01
RU2583134C2 (ru) 2016-05-10
RU2013148014A (ru) 2015-05-10
CN103582491A (zh) 2014-02-12
JP6410600B2 (ja) 2018-10-24
US20180000902A1 (en) 2018-01-04
EP2691109B1 (en) 2015-07-15
HUE025716T2 (en) 2016-04-28
CN103582491B (zh) 2016-12-07
BR112013024973B1 (pt) 2022-06-07

Similar Documents

Publication Publication Date Title
PL2691109T3 (pl) Zapobieganie hipoglikemii u pacjentów z cukrzycą typu 2
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
ZA201403795B (en) Formulations for the treatment of diabetes
PT2750699E (pt) Acelerómetro pendular
PL2779973T3 (pl) Interfejs pacjenta ze zmienną aplanacją
EP2543366A4 (en) FILM PREPARATION WITH MEDICAMENT WITH INDEPENDENT TASTE
SI2611458T1 (sl) Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2
IL228771A0 (en) Glycoside history and their use in the treatment of diabetes
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
IL223289A0 (en) Treatment of type 2 diabetes
IL230957B (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
GB201011095D0 (en) Improvements in or relating to ophthalmology
ZA201209701B (en) Improvements in or relating to ophthalmology
HK1206292A1 (en) Medicament administration
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
HK1257401A1 (zh) 用於治療糖尿病和相關病症的方法和組合物
GB201011094D0 (en) Improvements in or relating to ophthalmology
EP2455090A4 (en) MEANS TO INHIBIT THE INCREASE OF THE POSTPRANDIAL BLOOD INSULIN MIRROR
PL2536400T3 (pl) Lek zawierający miramistin
EP2402342A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES
EP2617726A4 (en) DIABETES THERAPEUTIC
EP2790704A4 (en) TREATMENT OF TYPE I AND TYPE II DIABETES
HK1198467A1 (en) Treatment of type 2 diabetes with fty720 fty720 2
PT2717872T (pt) Combinação sinérgica para o tratamento da diabetes mellitus tipo 2
HK1196953A1 (zh) 用於治療糖尿病的製劑